CABA.OQ
Latest Trade
14.22USDChange
1.46(+11.44%)Volume
41,998Today's Range
-
14.7252 Week Range
-
19.63As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 12.76 |
|---|---|
Open | 12.71 |
Volume | 41,998 |
3M AVG Volume | 1.90 |
Today's High | 14.72 |
Today's Low | 12.71 |
52 Week High | 19.63 |
52 Week Low | 5.55 |
Shares Out (MIL) | 24.06 |
Market Cap (MIL) | 306.95 |
Forward P/E | -9.66 |
Dividend (Yield %) | -- |
Cabaletta Bio Files For Offering Of $75 Mln Of Common Stock - SEC Filing
Cabaletta Bio Inc Files For Mixed Shelf Of Upto $250 Mln
Cabaletta Bio Reports Third Quarter 2020 Financial Results And Provides Business Update
Cabaletta Bio Inc. is a clinical stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.
Industry
Biotechnology & Drugs
Contact Info
2929 Arch St Ste 600
PHILADELPHIA, PA
19104-2857
United States
+1.267.7593100
https://www.cabalettabio.com/Executive Leadership
Steven Nichtberger
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Anup Marda
Chief Financial Officer
Gwendolyn Knowlton Binder-Scholl
Executive Vice President, Science & Technology
J. Brian Stalter
General Counsel
David J. Chang
Chief Medical Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 2.61 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -31.08 |
Return on Equity (TTM) | -29.92 |
* CABALETTA BIO AND ARTISAN BIO ANNOUNCE GENE EDITING RESEARCH AND COLLABORATION AGREEMENT TO DEVELOP NEXT-GENERATION CAAR T CELL THERAPIES
* CABALETTA BIO ANNOUNCES EXPANSION OF SPONSORED RESEARCH AGREEMENT WITH THE UNIVERSITY OF PENNSYLVANIA
* CABALETTA BIO RECEIVES FDA FAST TRACK DESIGNATION FOR DSG3-CAART FOR THE TREATMENT OF MUCOSAL PEMPHIGUS VULGARIS
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.